The new pan-European group of 73 regulators, companies and trial sites is backed by €66.8m in funding with a six-year goal.
Sen-Jam Pharmaceutical has reported positive preliminary outcomes from its Phase II trial of SJP-002C to treat upper ...
Evaxion Biotech has completed subject dosing in the Phase II trial of EVX-01, for the treatment of advanced melanoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback